NPC Clinical Trial
Official title:
The Phase Ib/II, Open-label, Multicenter Study of IBI310 (Anti-CTLA4 mAb) in Combination With Sintilimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma That Failed Prior Anti-PD-1/PD-L1 Therapy
Verified date | February 2023 |
Source | Innovent Biologics (Suzhou) Co. Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma that failed prior Anti-PD-1/PD-L1 therapy
Status | Completed |
Enrollment | 30 |
Est. completion date | February 6, 2023 |
Est. primary completion date | April 25, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Aged =18 years; 2. ECOG 0 ~ 1; 3. Histologically/cytologically confirmed R/M NPC; 4. Failed to prior Anti-PD-1 resistance; 5. Adequate organ and bone marrow function; 6. Expected survival =12 weeks; 7. Female subjects of childbearing age or male patients whose sex partners are women of childbearing age should take effective contraceptive measures throughout the treatment period and within 6 months after the last administration; 8. Subjects who sign the written informed consent form, and can abide by the visits and related procedures specified in the protocol. 9. At least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1). Exclusion Criteria: 1. Had tumors other than NPC within the past 5 years. 2. Had allogeneic organ or stem cell transplantation. 3. The presence of uncontrolled life-threatening illness 4. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. 5. Patients who have used large doses of glucocorticoids, anti-cancer monoclonal antibodies, and other immunosuppressive agents within 4 weeks. 6. HIV positive. 7. Patients with significantly lower heart, liver, lung, kidney and bone marrow function. 8. Severe, uncontrolled medical conditions and infections. 9. At the same time using other test drugs or in other clinical trials. 10. Refusal or inability to sign informed consent to participate in the trial. 11. Other treatment contraindications. 12. Emotional disturbance or mental illness, no civil capacity or limited capacity for civil conduct. 13. Hepatitis B surface antigen (HBsAg) positive and HBVDNA =1000cps/ml. 14. Patients with positive HCV antibody test results can only be included in the study when the polymerase chain reaction of HCV RNA is negative. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Innovent Biologics (Suzhou) Co. Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ORR(Objective response rate) | Investigator evaluated ORR per RECIST V1.1 | Up to 2 years | |
Secondary | DOR(Duration of Response) | defined as the time from the first documented objective response to the first documented progressive disease or death of any cause, whichever occurs first; | Up to 2 years | |
Secondary | PFS (Progress Free Survival) | defined as the time from randomization to the first documented progressive disease or death of any cause, whichever occurs first; | Up to 2 years | |
Secondary | OS (Overall Survival) | defined as the time from randomization to death of any cause in subjects without receiving any immunotherapy outside the study protocol for first-line treatment of advanced HCC; | Up to 2 years | |
Secondary | DCR(Disease control rate) | defined as the proportion of patients whose best response is CR, PR, and stable disease (SD) non-CR/non-PD | Up to 2 years | |
Secondary | TTR(Time to progress) | defined as the time from randomization to the first documented and confirmed objective response (CR or PR) | Up to 2 years | |
Secondary | TEAE(Treatment Emergent Adverse Event)/SAE(Serious Adverse Event) | Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0, 2017) grade; | Up to 2 years | |
Secondary | Changes of Quality of life, according to EORTC QLQ-C30 | According to EORTC QLQ-C30 | Up to 2 years | |
Secondary | Changes of Quality of life, according to EORTC QLQ-H&N35 | According to EORTC QLQ-H&N35 | Up to 2 years | |
Secondary | ADAs | The immunogenicity of IBI310 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs) | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03352778 -
IMRT vs 2DRT for NPC Patients
|
||
Active, not recruiting |
NCT03734809 -
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
|
Phase 2 | |
Recruiting |
NCT03158324 -
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
|
Phase 2 | |
Recruiting |
NCT03919552 -
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
|
Phase 3 | |
Not yet recruiting |
NCT04284332 -
Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)
|
Phase 2 | |
Recruiting |
NCT05983432 -
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
|
Phase 1 | |
Completed |
NCT03973723 -
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
|
||
Active, not recruiting |
NCT01744587 -
Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients
|
N/A |